Skip to main content

Psoriatic arthritis

      Early diagnosis of arthritis improves outcomes and quality of life in patients with psoriasis. A longitudinal cohort study shows that the development of PsA within clinically meaningful time frames can be predicted with reasonable accuracy for psoriasis patients.
      Each pharmaceutical company has spent months and years preparing to present and highlight their featured clinical trials and abstracts at ACR 2020.  This is our selection of their best studies for you to review and evaluate as part of your to-do list.
      RT @drpnash: Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA

      Peter Nash drpnash

      4 years 10 months ago
      Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
      Inadequate Response in Spondylitis: Dr. Olga Petryna

      Dr. Petryna discusses two abstracts being presented at the ACR 2020 meeting: #0359 and #0371

      Axial Involvement in Psoriatic Arthritis: Dr. Eric Ruderman Perspective

      Dr. Eric Ruderman, Chicago, IL., provides his perspective on ACR 2020 coverage of axial involvement in Psoriatic Arthritis. During his remarks, he discusses ACR abstracts #0344, #1372, #2025 and #0505. 

      Here is the last of our QD Clinics in Podcast form, just before we start ACR2020 coverage. In this compilation from the past week we talk about - HIV and arthritis - Hyperuricemia in PsA - An odd kind of dermatomyositis - Running out of options in Difficult RA Listen here or on your podcast program in your car.
      Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Ps

      Dr. John Cush RheumNow

      4 years 10 months ago
      Presented at EADV Dermatology Congress - Mirikizumab, IL-23 inhibitor, shown superior to placebo & Secukinumab in Psoriasis. 465 patients given either PBO, MIR (2 doses) or SEC. Wk 52 MIR PASI90 PASI 90 (81%) vs SEC 69% https://t.co/EBCBUjkyWG
      The risk of serious infections (SIE) in RA patients given anti-TNF (TNFi) therapy is not static, instead it has been shown to be greatest in the first 6 months of use according to a recent report in Rheumatology. 
      ×